XML 18 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets	9 Months Ended
Sep. 30, 2023
Other Current Assets [Abstract]
Other Current Assets	4. Other Current Assets As of September 30, 2023, other current assets included prepaid expenses of $1.8 million, comprised primarily of prepayments of $1.3 million made for the Company’s clinical trials for BP1002 in separate clinical trials for lymphoma and AML and BP1001-A in solid tumors. Additionally, the Company had prepaid insurance expenses of $0.4 million and other prepaid expenses of $0.1 million. As of December 31, 2022, other current assets included prepaid expenses of $1.6 million, comprised primarily of prepayments of $1.3 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, BP1001-A in solid tumors and prexigebersen in AML as well as prepaid insurance of $0.3 million.

Other Current Assets

9 Months Ended

Sep. 30, 2023

4. Other Current Assets

As of September 30, 2023, other current assets included prepaid expenses of $1.8 million, comprised primarily of prepayments of $1.3 million made for the Company’s clinical trials for BP1002 in separate clinical trials for lymphoma and AML and BP1001-A in solid tumors. Additionally, the Company had prepaid insurance expenses of $0.4 million and other prepaid expenses of $0.1 million. As of December 31, 2022, other current assets included prepaid expenses of $1.6 million, comprised primarily of prepayments of $1.3 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, BP1001-A in solid tumors and prexigebersen in AML as well as prepaid insurance of $0.3 million.